| KDM5-IN-1 |
1628210-26-3 |
1628210-26-3 |
| SYP-5 |
1384268-04-5 |
1384268-04-5 |
| ACTB-1003 |
ACTB-1003 |
939805-30-8 |
| 5H-Benzocycloheptene-8-carboxylic acid, 3,4,6-trihydroxy-2-methoxy-5-oxo-, hexyl ester |
1416324-85-0 |
1416324-85-0 |
| AMZ30 |
CS-2122 |
1313613-09-0 |
| Ca2+ channel agonist 1 |
1402821-24-2 |
1402821-24-2 |
| PSI7409 |
1015073-42-3 |
1015073-42-3 |
| PF-CBP1 (hydrochloride) |
PF-CBP1 |
2070014-93-4 |
| [(3R)-3-Amino-4-[(3-hexylphenyl)amino]-4-oxobutyl]-phosphonic acid mono(trifluoroacetate) |
[(3R)-3-氨基-4-[(3-己基苯基)氨基]-4-氧代丁基]-膦酸单(三氟乙酸盐) |
909725-62-8 |
| GSK-3 inhibitor 1 |
3-(9-氟-1,2,3,4-四氢吡咯并[3,2,1-JK][1,4]苯并二氮杂卓-7-基)-4-咪唑并[1,2-A]吡啶-3-基-1H-吡咯-2,5-二酮单盐酸盐 |
603272-51-1 |
| OTS514 |
OTS514 |
1338540-55-8 |
| BMS-582949 (hydrochloride) |
BMS-582949 (HYDROCHLORIDE) |
912806-16-7 |
| ZL0420 |
化合物ZL0420 |
2229039-45-4 |
| UNC-2371A |
1429882-07-4 |
1429882-07-4 |
| PQR620 |
PQR620游离态 |
1927857-56-4 |
| (24R)-MC976 |
(1ALPHA,3BETA,5Z,7E,24R)-24-环丙基-9,10-开环胆甾-5,7,10(19)-三烯-1,3,24-三醇 |
112828-09-8 |
| (3alpha,5beta,12alpha)-3,12-Dihydroxy-7-oxocholan-24-oic acid methyl ester |
(3ALPHA,5BETA,12ALPHA)-3,12-二羟基-7-酮基胆烷-24-酸甲酯 |
10538-65-5 |
| HOE-32020 |
HOE 32020 |
23554-99-6 |
| VTX-27 |
1321924-70-2 |
1321924-70-2 |
| 3H-IMidazo[4,5-b]pyridine, 6-chloro-7-[4-[(4-chlorophenyl)Methyl]-1-piperazinyl]-2-(1,3-diMethyl-1H-pyrazol-4-yl)- |
CS-2683 |
1402709-93-6 |
